At the time of writing, Akebia Therapeutics Inc [AKBA] stock is trading at $2.80, up 7.28%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AKBA shares have gain 15.23% over the last week, with a monthly amount glided 35.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akebia Therapeutics Inc [NASDAQ: AKBA] stock has seen the most recent analyst activity on April 28, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $7. Previously, Jefferies started tracking the stock with Buy rating on April 01, 2025, and set its price target to $6. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $3.75 on August 28, 2023. Piper Sandler upgraded its rating to a Overweight and raised its price target to $4 on May 31, 2023. Piper Sandler downgraded its rating to Neutral for this stock on March 31, 2022, and downed its price target to $2. In a note dated March 31, 2022, Needham downgraded an Hold rating on this stock.
For the past year, the stock price of Akebia Therapeutics Inc fluctuated between $0.80 and $2.90. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Akebia Therapeutics Inc [NASDAQ: AKBA] shares were valued at $2.80 at the most recent close of the market. An investor can expect a potential return of 132.14% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
According to Akebia Therapeutics Inc [NASDAQ:AKBA], the company’s sales were 184.91M for trailing twelve months, which represents an 75.84% jump. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is 1.67 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Akebia Therapeutics Inc [NASDAQ:AKBA] has a current ratio of 2.23. Further, the Quick Ratio stands at 2.02, while the Cash Ratio is 1.24. Considering the valuation of this stock, the price to sales ratio is 3.98, the price to book ratio is 29.80.
Transactions by insiders
Recent insider trading involved Butler John P., CEO and President, that happened on Mar 03 ’25 when 46409.0 shares were sold. SVP, Chief Medical Officer, Burke Steven Keith completed a deal on Mar 03 ’25 to sell 7144.0 shares. Meanwhile, Officer Burke Steven Keith bought 7144.0 shares on Mar 03 ’25.
